Background-This clinical investigation was performed to compare the effects of permanent dual-chamber cardiac pacing with pharmacological therapy in patients with recurrent vasovagal syncope. Methods and Results-Patients from 14 centers were randomized to receive either a DDD pacemaker provided with rate-drop response function or the -blocker atenolol at the dosage of 100 mg once a day. Inclusion criteria were age Ͼ35 years, Ն3 syncopal spells in the preceding 2 years, and positive response to tilt